NCT01128218View on ClinicalTrials.gov

A Study of the Specificity and Sensitivity of 5- Aminolevulinic Acid (ALA) Fluorescence in Malignant Brain Tumors

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

33

Participants

Timeline

Start Date

March 31, 2011

Primary Completion Date

February 28, 2021

Study Completion Date

February 28, 2021

Conditions
Brain Neoplasms
Interventions
DRUG

Tumor fluorescence

"Oral doses in phase 1 study of 10mg/kg, 20 mg/kg, 30 mg/kg, 40 mg/kg and 50 mg/kg.~Recommended oral dose of phase 1 will be used in phase 2"

Trial Locations (1)

62702

Southern Illinois University School of Medicine, Springfield

Sponsors
All Listed Sponsors
collaborator

DUSA Pharmaceuticals, Inc.

INDUSTRY

lead

Southern Illinois University

OTHER